Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Acumen Pharmaceuticals, Inc.ABOS · Entity 6281 | Director | June 15, 2022 | June 17, 2022 |
| Rapport Therapeutics, Inc.RAPP · Entity 4394 | Chief Medical Officer | February 02, 2026 | February 04, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Acumen Pharmaceuticals, Inc.
Report date June 15, 2022 · Filed June 17, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.59 · Expires 2032-06-14 | Direct | 25,000 |
Reported balance
After 2022-06-15 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2022-06-15 · Grant · Acquired 25,000 · Balance 25,000 F1: The shares subject to the option will vest on on the earlier of June 15, 2023 or the 2023 annual stockholder meeting, subject to the Reporting Person's continuous service through each such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares subject to the option will vest on on the earlier of June 15, 2023 or the 2023 annual stockholder meeting, subject to the Reporting Person's continuous service through each such vesting date.
Rapport Therapeutics, Inc.
Report date February 02, 2026 · Filed February 04, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $27.75 · Expires 2036-02-02 | Direct | 130,000 |
Reported balance
After 2026-02-02 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-02-02 · Grant · Acquired 130,000 · Balance 130,000 F1: The shares underlying this option shall vest and become exercisable in forty-eight (48) equal monthly installments following January 1, 2026, subject to the Reporting Person's continued service on each such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares underlying this option shall vest and become exercisable in forty-eight (48) equal monthly installments following January 1, 2026, subject to the Reporting Person's continued service on each such vesting date.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Prevail Therapeutics Inc.
Report date January 22, 2021 · Filed January 26, 2021
Section 16 reporting ended · disclosed 2021-01-26. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.18 | Direct | 0 |
Reported balance
After 2021-01-22 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2021-01-22 · Disposition to issuer · Disposed 400,342 · Balance 0 F1: Pursuant to the terms of the Merger Agreement, and as of immediately prior to the Effective Time, each of these options, whether or not vested, was automatically cancelled, by virtue of the Merger and without any action on the part of the Reporting Person, and the Reporting Person was entitled to receive (A) an amount of cash (less applicable tax withholdings) equal to the product of (i) the excess, if any, of $22.50 per share of common stock underlying such stock option, net in cash, without interest, over the applicable exercise price per share underlying such stock option multiplied by (ii) the total number of shares subject to such stock option, and (B) one contingent value right per share for each share subject to such stock option immediately prior to the Effective Time (without regard to vesting). |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $10.26 | Direct | 0 |
Reported balance
After 2021-01-22 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2021-01-22 · Disposition to issuer · Disposed 122,439 · Balance 0 F1: Pursuant to the terms of the Merger Agreement, and as of immediately prior to the Effective Time, each of these options, whether or not vested, was automatically cancelled, by virtue of the Merger and without any action on the part of the Reporting Person, and the Reporting Person was entitled to receive (A) an amount of cash (less applicable tax withholdings) equal to the product of (i) the excess, if any, of $22.50 per share of common stock underlying such stock option, net in cash, without interest, over the applicable exercise price per share underlying such stock option multiplied by (ii) the total number of shares subject to such stock option, and (B) one contingent value right per share for each share subject to such stock option immediately prior to the Effective Time (without regard to vesting). |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $16.91 | Direct | 0 |
Reported balance
After 2021-01-22 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2021-01-22 · Disposition to issuer · Disposed 89,000 · Balance 0 F1: Pursuant to the terms of the Merger Agreement, and as of immediately prior to the Effective Time, each of these options, whether or not vested, was automatically cancelled, by virtue of the Merger and without any action on the part of the Reporting Person, and the Reporting Person was entitled to receive (A) an amount of cash (less applicable tax withholdings) equal to the product of (i) the excess, if any, of $22.50 per share of common stock underlying such stock option, net in cash, without interest, over the applicable exercise price per share underlying such stock option multiplied by (ii) the total number of shares subject to such stock option, and (B) one contingent value right per share for each share subject to such stock option immediately prior to the Effective Time (without regard to vesting). |
Filing footnotes · ownership attribution and instrument terms
F1: Pursuant to the terms of the Merger Agreement, and as of immediately prior to the Effective Time, each of these options, whether or not vested, was automatically cancelled, by virtue of the Merger and without any action on the part of the Reporting Person, and the Reporting Person was entitled to receive (A) an amount of cash (less applicable tax withholdings) equal to the product of (i) the excess, if any, of $22.50 per share of common stock underlying such stock option, net in cash, without interest, over the applicable exercise price per share underlying such stock option multiplied by (ii) the total number of shares subject to such stock option, and (B) one contingent value right per share for each share subject to such stock option immediately prior to the Effective Time (without regard to vesting).
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 02, 2026 Filed Feb 4, 2026 21:15 UTC | Rapport Therapeutics, Inc. RAPP · Entity 4394 | GrantStock Option (Right to Buy) · Derivative | 130,000 | $0.00 Strike: $27.75 | $0.00 |
DisclosureSEC source: 0001193125-26-037618 · ownership.xml · derivative · entry 1 Sevigny Jeffrey · CIK 0001778483 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 130,000 Underlying: Common Stock · 130,000 shares Expires 2036-02-02 F1 · derivative.exercise_date: The shares underlying this option shall vest and become exercisable in forty-eight (48) equal monthly installments following January 1, 2026, subject to the Reporting Person's continued service on each such vesting date. Read SEC document |
| April 01, 2025 Filed Apr 3, 2025 21:00 UTC | Rapport Therapeutics, Inc. RAPP · Entity 4394 | GrantStock Option (Right to Buy) · Derivative | 300,000 | $0.00 Strike: $9.56 | $0.00 |
DisclosureSEC source: 0000950170-25-050557 · ownership.xml · derivative · entry 1 Sevigny Jeffrey · CIK 0001778483 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 300,000 Underlying: Common Stock · 300,000 shares Expires 2035-04-01 F1 · derivative.exercise_date: 25% of the shares underlying this option shall vest and become exercisable on March 3, 2026, with the remaining shares vesting in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date. Read SEC document |
| June 15, 2022 Filed Jun 17, 2022 20:24 UTC | Acumen Pharmaceuticals, Inc. ABOS · Entity 6281 | GrantStock Option (right to buy) · Derivative | 25,000 | $0.00 Strike: $3.59 | $0.00 |
DisclosureSEC source: 0001209191-22-037870 · doc4.xml · derivative · entry 1 Sevigny Jeffrey · CIK 0001778483 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2032-06-14 F1 · derivative.exercise_date: The shares subject to the option will vest on on the earlier of June 15, 2023 or the 2023 annual stockholder meeting, subject to the Reporting Person's continuous service through each such vesting date. Read SEC document |
| June 30, 2021 Filed Jul 2, 2021 20:19 UTC | Acumen Pharmaceuticals, Inc. ABOS · Entity 6281 | GrantStock Option (Right to Buy) · Derivative | 34,000 | $0.00 Strike: $16.00 | $0.00 |
DisclosureSEC source: 0001209191-21-044952 · doc4.xml · derivative · entry 1 Sevigny Jeffrey · CIK 0001778483 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,000 Underlying: Common Stock · 34,000 shares Expires 2031-06-30 F1 · derivative.exercise_date: The shares subject to the option will vest in equal monthly installments over a three year period such that the option is fully vested on the third anniversary of the date of grant, subject to the Reporting Person's continuous service through each such vesting date and shall vest and become immediately exercisable prior to the effectiveness of a change in control. Read SEC document |
| January 22, 2021 Filed Jan 26, 2021 17:09 UTC | Prevail Therapeutics Inc. PRVL · Entity 11821 | Disposition to issuerStock Option (Right to Buy) · Derivative | 89,000 | $0.00 Strike: $16.91 | $0.00 |
DisclosureSEC source: 0001209191-21-005418 · doc4.xml · derivative · entry 3 Sevigny Jeffrey · CIK 0001778483 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 89,000 shares Expires not disclosed F1 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, and as of immediately prior to the Effective Time, each of these options, whether or not vested, was automatically cancelled, by virtue of the Merger and without any action on the part of the Reporting Person, and the Reporting Person was entitled to receive (A) an amount of cash (less applicable tax withholdings) equal to the product of (i) the excess, if any, of $22.50 per share of common stock underlying such stock option, net in cash, without interest, over the applicable exercise price per share underlying such stock option multiplied by (ii) the total number of shares subject to such stock option, and (B) one contingent value right per share for each share subject to such stock option immediately prior to the Effective Time (without regard to vesting). F1 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, and as of immediately prior to the Effective Time, each of these options, whether or not vested, was automatically cancelled, by virtue of the Merger and without any action on the part of the Reporting Person, and the Reporting Person was entitled to receive (A) an amount of cash (less applicable tax withholdings) equal to the product of (i) the excess, if any, of $22.50 per share of common stock underlying such stock option, net in cash, without interest, over the applicable exercise price per share underlying such stock option multiplied by (ii) the total number of shares subject to such stock option, and (B) one contingent value right per share for each share subject to such stock option immediately prior to the Effective Time (without regard to vesting). Read SEC document |
| January 22, 2021 Filed Jan 26, 2021 17:09 UTC | Prevail Therapeutics Inc. PRVL · Entity 11821 | Disposition to issuerStock Option (Right to Buy) · Derivative | 122,439 | $0.00 Strike: $10.26 | $0.00 |
DisclosureSEC source: 0001209191-21-005418 · doc4.xml · derivative · entry 2 Sevigny Jeffrey · CIK 0001778483 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 122,439 shares Expires not disclosed F1 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, and as of immediately prior to the Effective Time, each of these options, whether or not vested, was automatically cancelled, by virtue of the Merger and without any action on the part of the Reporting Person, and the Reporting Person was entitled to receive (A) an amount of cash (less applicable tax withholdings) equal to the product of (i) the excess, if any, of $22.50 per share of common stock underlying such stock option, net in cash, without interest, over the applicable exercise price per share underlying such stock option multiplied by (ii) the total number of shares subject to such stock option, and (B) one contingent value right per share for each share subject to such stock option immediately prior to the Effective Time (without regard to vesting). F1 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, and as of immediately prior to the Effective Time, each of these options, whether or not vested, was automatically cancelled, by virtue of the Merger and without any action on the part of the Reporting Person, and the Reporting Person was entitled to receive (A) an amount of cash (less applicable tax withholdings) equal to the product of (i) the excess, if any, of $22.50 per share of common stock underlying such stock option, net in cash, without interest, over the applicable exercise price per share underlying such stock option multiplied by (ii) the total number of shares subject to such stock option, and (B) one contingent value right per share for each share subject to such stock option immediately prior to the Effective Time (without regard to vesting). Read SEC document |
| January 22, 2021 Filed Jan 26, 2021 17:09 UTC | Prevail Therapeutics Inc. PRVL · Entity 11821 | Disposition to issuerStock Option (Right to Buy) · Derivative | 400,342 | $0.00 Strike: $0.18 | $0.00 |
DisclosureSEC source: 0001209191-21-005418 · doc4.xml · derivative · entry 1 Sevigny Jeffrey · CIK 0001778483 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 400,342 shares Expires not disclosed F1 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, and as of immediately prior to the Effective Time, each of these options, whether or not vested, was automatically cancelled, by virtue of the Merger and without any action on the part of the Reporting Person, and the Reporting Person was entitled to receive (A) an amount of cash (less applicable tax withholdings) equal to the product of (i) the excess, if any, of $22.50 per share of common stock underlying such stock option, net in cash, without interest, over the applicable exercise price per share underlying such stock option multiplied by (ii) the total number of shares subject to such stock option, and (B) one contingent value right per share for each share subject to such stock option immediately prior to the Effective Time (without regard to vesting). F1 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, and as of immediately prior to the Effective Time, each of these options, whether or not vested, was automatically cancelled, by virtue of the Merger and without any action on the part of the Reporting Person, and the Reporting Person was entitled to receive (A) an amount of cash (less applicable tax withholdings) equal to the product of (i) the excess, if any, of $22.50 per share of common stock underlying such stock option, net in cash, without interest, over the applicable exercise price per share underlying such stock option multiplied by (ii) the total number of shares subject to such stock option, and (B) one contingent value right per share for each share subject to such stock option immediately prior to the Effective Time (without regard to vesting). Read SEC document |
| February 19, 2020 Filed Mar 11, 2020 16:49 UTC | Prevail Therapeutics Inc. PRVL · Entity 11821 | GrantStock Option (Right to Buy) · Derivative | 89,000 | $0.00 Strike: $16.91 | $0.00 |
DisclosureSEC source: 0001209191-20-018118 · doc4.xml · derivative · entry 1 Sevigny Jeffrey · CIK 0001778483 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 89,000 Underlying: Common Stock · 89,000 shares Expires 2030-02-19 F1 · derivative.exercise_date: 25% of the total number of shares underlying the option vest and become exercisable on February 19, 2021 and an additional 1/48th of the total number of shares underlying the option shall vest and become exercisable on the same date of each of the thirty-six (36) consecutive months thereafter subject, in all cases, to the Reporting Person providing continuous service with the Issuer on each such date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.